Rituximab Treatment of Primary Cutaneous Follicle Center Lymphoma: A Retrospective Review.

Siru WangJonah W PerlmutterJames JohnstonZoann NugentMarni C Wiseman

Published in: Journal of cutaneous medicine and surgery (2022)

Despite the potential for rituximab-containing chemoimmunotherapy to yield adverse effects, it is effective in achieving a prolonged clinical remission in patients with PCFCL. It remains a reasonable treatment option for diffuse, extensive, or treatment-resistant disease.

Keyphrases

diffuse large b cell lymphoma
risk assessment
low grade
chronic lymphocytic leukemia
human health
smoking cessation